Vancouver, British Columbia--(Newsfile Corp. - March 29, 2021) - Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the Company has been added to the Horizons Psychedelic Stock Index ETF ("PSYK" or the "ETF") and its underlying index, the Horizons North American Psychedelics Index (the "Index").
Philip Young, CEO and Director of Lobe, stated, "We are pleased to have been added to the ETF and Index, and look forward to the added market exposure this will bring the Company. Lobe continues to pursue its objectives for the development of psychedelics to improve mental health and wellness."
PSYK is an ETF which seeks to replicate, to the extent possible and net of expenses, the performance of the Index. The Index is a proprietary index owned and operated by Horizons ETFs, and Solactive AG is the independent calculation agent. The Index, which rebalances each calendar quarter, has been designed to provide a measure of the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry.
Information on PSYK is available at https://www.HorizonsETFs.com/PSYK. The current holdings of the Index are available at: https://www.solactive.com/ordinary-index-rebalancing-in-the-north-american-psychedelics-index-march-2021/.
About Lobe Sciences Ltd.
Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information please contact:
Lobe Sciences Ltd.
Philip J Young, CEO
Tel: (949) 505-5623
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the Company's development of psychedelics to improve the health of patients, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.